RadNet Lifts 2026 Guidance as Digital Health Growth Accelerates—AI and Advanced Imaging Propel Record Quarter
Record First Quarter Drives Upward Guidance Revision
RadNet (NASDAQ: RDNT) announced a record-setting first quarter for 2026, prompting a hike in its financial outlook for full-year revenue, adjusted EBITDA, and free cash flow in its Imaging Center segment. This momentum stems from robust demand for advanced imaging procedures and rapid growth in the company’s Digital Health business.
Imaging Center Revenue Rises Over 22% as Advanced Modalities Lead
Driven by a 19.7% jump in aggregate advanced imaging volumes—spanning MRI, CT, and PET/CT—RadNet’s first-quarter revenue climbed to $575.6 million, up 22.1% from the same period last year. Same-center advanced imaging volumes delivered an 8.2% increase, supporting an overall shift toward higher-value modalities. Advanced imaging now comprises 29.3% of procedural volume versus 26.9% a year ago, echoing sustained demand across the company’s network of over 435 outpatient locations.
| Modality | Q1 2026 Procedures | Q1 2025 Procedures | Year-over-Year Change |
|---|---|---|---|
| MRI | 538,043 | 447,330 | +20.3% |
| CT | 319,201 | 271,170 | +17.7% |
| PET/CT | 27,572 | 20,389 | +35.2% |
| Total Volume | 3,020,955 | 2,742,973 | +10.1% |
Digital Health: ARR Surges, AI Adoption Set to Reshape Workflow
Digital Health revenue soared 51.5% year-over-year to $29.1 million, while Annual Recurring Revenue (ARR) nearly doubled to $96.9 million as of March 31, 2026. A key driver: the March acquisition of France’s Gleamer SAS, expanding RadNet’s clinical AI portfolio. Management expects over 70% of RadNet studies to employ AI solutions by year-end, aiming to channel workflow improvements and cost savings directly into patient care. Notably, new DeepHealth contracts signed in Q1 totaled $16 million in value, reflecting healthy demand from third-party customers.
| Digital Health Metric | Q1 2026 | Q1 2025 | Change (%) |
|---|---|---|---|
| Revenue ($M) | 29.1 | 19.2 | +51.5% |
| ARR ($M) | 96.9 | 49.8 | +94.6% |
Adjusted EBITDA Leaps 36% Despite Investment in Digital Expansion
Adjusted EBITDA for the company hit $63.3 million—up 36.3% year-over-year—even after absorbing intentional infrastructure investments in Digital Health that tempered its segment profitability for the quarter. Adjusted diluted loss per share improved to $(0.28) from $(0.34) a year earlier, while losses from one-time items (such as acquisition costs and R&D) narrowed overall net losses. Free cash flow guidance was revised upward to $112–$122 million for 2026, reinforcing positive operating trends.
| 2026 Imaging Center Guidance | Original Range | Revised Range |
|---|---|---|
| Total Net Revenue ($M) | 2,325 – 2,375 | 2,355 – 2,405 |
| Adjusted EBITDA ($M) | 335 – 348 | 340 – 353 |
| Free Cash Flow ($M) | 105 – 115 | 112 – 122 |
Capital and Joint Ventures: Building for the Future
With a cash balance of $455.3 million and a leverage ratio below 2.0, RadNet stands on solid financial ground to support expansion. The recently announced joint venture with Trinity Health’s Saint Alphonsus Health System in Idaho and integration of DeepHealth AI products marks a strategic push—underscoring RadNet’s ambition to be the technology partner of choice for health systems across the U.S.
Key Takeaway: RadNet’s AI and Imaging Momentum Outpaces Industry Norms
This quarter’s upward revision in guidance, strong cash position, and growing AI-driven Digital Health revenues highlight a business outpacing industry growth—fueled by both organic demand and targeted tech expansion. Investors may want to monitor RadNet’s progress as AI adoption accelerates across radiology workflows and as the company leverages its scale to drive both top-line and margin improvements. With more than 3 million procedures in the quarter and increasing integration of intelligent automation, RadNet’s trajectory appears poised for continued evolution throughout 2026 and beyond.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI